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Preclinical Evaluation of Novel All-in-one Formulations of 5-Fluorouracil and 
Folinic Acid with Reduced Toxicity Profiles - Supplementary Data 
Abstract 
Objectives: 5-Fluorouracil (5-FU) in combination with its synergistic biomodulator folinic acid maintains a 
pivotal position in cancer chemotherapy. However, clinical limitations persist with the administration of 
these drugs in combination including phlebitis and catheter blockages, which are associated with 
reduced efficacy and/or quality of life for patients. We have previously reported novel all-in-one, pH 
neutral, parenteral 5-FU and folinic acid formulations (termed Fluorodex) incorporating beta-cyclodextrins. 
Fluorodex maintains potency while overcoming the accepted incompatibility of 5-FU and folinic acid. 
Methods: We performed toxicological, pharmacokinetic and biodistribution, and efficacy evaluations of 
Fluorodex compared to 5-FU:folinic acid using several administration routes and schedules in two rodent 
models. These were compared to dose-matched sequential administration of 5-FU:folinic acid. 
Results: Fluorodex showed bioequivalence to 5-FU:folinic acid as assessed by tissue distribution and 
pharmacokinetics of 5-FU, but was generally better tolerated as determined by weight loss, hematological 
and other clinical parameters. Compared to 5-FU:folinic acid, Fluorodex was also associated with reduced 
phlebitis using a rabbit ear vein model. Furthermore, equivalent to enhanced efficacy of Fluorodex 
compared to 5-FU:folinic acid against human carcinoma tumour models in mice was observed. 
Conclusions: These novel all-in-one formulations represent a superior injectable form of 5- FU that allows 
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Table S1 Haematology parameters – male rats 
 β-CD(HP) control FD(HP) 5FU:FA 
 Mean SD N Mean SD N Mean SD N 
WBC (x109/L) 8.43 1.39 4 2.40 1.10 4 2.33 2.70 4 
Neutrophils 1.08 0.30 4 0.95 1.70 4 1.45 2.70 4 
Lymphocytes 7.03 1.03 4 1.35 0.68 4 0.90 0.54 4 
Monocytes 0.23 0.10 4 0.10 0.00 4 0.10 0.00 4 
Eosinophils 0.1 0.00 4 0.1 0.00 4 0.1 0.00 4 
RBC (x1012/L) 6.79 0.28 4 6.30 1.73 4 5.29 1.95 4 
Hgb (g/L) 144.00 4.69 4 135.00 35.52 4 116.00 44.58 4 
Hct (L/L) 0.43 0.02 4 0.39 0.10 4 0.33 0.13 4 
MCV (fL) 62.95 1.41 4 61.80 1.50 4 61.30 2.51 4 
MCH (pg) 21.20 0.32 4 21.45 0.31 4 21.88 0.39 4 
MCHC (g/L) 336.75 4.11 4 347.50 3.51 4 357.25 8.96 4 
Plt (x109/L) 1120.50 133.68 4 315.00 527.44 3 111.25 216.50 4 
WBC: while blood cell; RBC: red blood cell; Hgb: hemoglobin; Hct: hematocrit; MCV: mean 
corpuscular volume; MCH: mean corpuscular hemoglobin; MCHC: mean corpuscular 
hemoglobin concentration; Plt: platelets.  
  
Table S2 Haematology parameters – female rats 
 β-CD(HP) control FD(HP) 5FU:FA 
 Mean SD N Mean SD N Mean SD N 
WBC (x109/L) 5.95 0.70 4 2.30 0.69 4 1.10 0.35 4 
Neutrophils 0.75 0.39 4 0.10 0.00 4 0.1 0.00 4 
Lymphocytes 5.08 0.710 4 2.15 0.73 4 1.10 0.35 4 
Monocytes 0.10 0.00 4 0.10 0.00 4 0.1 0.00 4 
Eosinophils 0.10 0.00 4 0.1 0.00 4 0.1 0.00 4 
RBC (x1012/L) 6.22 0.28 4 5.29 0.20 4 4.86 0.22 4 
Hgb (g/L) 132.00 6.38 4 113.25 5.38 4 100.75 3.50 4 
Hct (L/L) 0.39 0.01 4 0.31 0.01 4 0.29 0.01 4 
MCV (fL) 62.60 1.89 4 57.93 0.92 4 59.60 0.66 4 
MCH (pg) 21.23 0.83 4 21.48 0.33 4 20.78 0.76 4 
MCHC (g/L) 339.00 6.22 4 370.50 4.43 4 348.25 9.18 4 
Plt (x109/L) 1049.50 92.31 4 44.50 16.84 4 3.25 4.50 4 
WBC: while blood cell; RBC: red blood cell; Hgb: hemoglobin; Hct: hematocrit; MCV: mean 
corpuscular volume; MCH: mean corpuscular hemoglobin; MCHC: mean corpuscular 
hemoglobin concentration; Plt: platelets.  
